🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchMazdutide (LY3305677) — GLORY trials in Chinese population Page 3

Mazdutide (LY3305677) — GLORY trials in Chinese population

TrialNerd_Beth Sun, May 31, 2026 at 8:02 PM 14 replies 547 viewsPage 3 of 3
SandraNC_45
Member
312
1,345
Sep 2024
Charlotte, NC
Jun 2, 2026 at 8:22 PM#11
Dr.ReproEndo said:
Relative and absolute effects need reading together.

Genuinely useful, thank you. I had the facts and not the framework. Adding it to my notes with a link back to this thread.

49 24FranDenver, Dr.BariatricHTX, LindaRN_retired and 46 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Jun 4, 2026 at 5:21 AM#12

From the other side of the consultation, briefly. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

48 23KristenIndy, MarkLI_maint, Dr.PeteFamMed and 45 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Jun 5, 2026 at 2:19 PM#13
lisa_labSD said:
The gap between trial results and real-world results is consistent and it is not fraud.

Worth saying that the confident version of this is more useful to the person writing it than to the person reading it.

47 22SurmountFan_IN, PeptideChemSF, A1cHero_PHX and 44 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Jun 6, 2026 at 11:19 PM#14

Adding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

46 21Dr.RaviCardio, jennifer_SEA, tyler_CSCS and 43 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 8, 2026 at 8:19 AM#15

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Tagging this one for the weekly digest.

45 20PurityPaulOR, MaxMetOK, MounjBrad and 42 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register